Clovis Oncology Inc. (NASDAQ:CLVS) shares fell 2.4% on Thursday . The company traded as low as $14.45 and last traded at $14.66, with a volume of 617,159 shares trading hands. The stock had previously closed at $15.02.

A number of research firms have weighed in on CLVS. Piper Jaffray Cos. reiterated a “hold” rating on shares of Clovis Oncology in a research report on Sunday, May 8th. Credit Suisse Group AG began coverage on shares of Clovis Oncology in a research report on Monday, April 18th. They set an “outperform” rating on the stock. WallachBeth Capital cut their price objective on shares of Clovis Oncology from $30.00 to $22.00 and set a “hold” rating on the stock in a research report on Monday, May 9th. Zacks Investment Research cut shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Clovis Oncology in a research report on Wednesday, April 13th. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $29.25.

The company’s market capitalization is $564.26 million. The stock’s 50 day moving average price is $14.73 and its 200 day moving average price is $18.67.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.39) by $0.22. The company’s revenue for the quarter was up NaN% on a year-over-year basis. During the same period in the previous year, the business posted ($1.86) earnings per share. On average, equities research analysts predict that Clovis Oncology Inc. will post ($8.00) EPS for the current fiscal year.

A number of hedge funds and institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock worth $1,265,000 after buying an additional 3,125 shares during the period. California State Teachers Retirement System increased its stake in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the period. Trexquant Investment LP bought a new stake in shares of Clovis Oncology during the fourth quarter worth about $3,170,000. Finally, Oxford Asset Management increased its stake in shares of Clovis Oncology by 344.0% in the fourth quarter. Oxford Asset Management now owns 93,893 shares of the biopharmaceutical company’s stock worth $3,304,000 after buying an additional 72,748 shares during the period.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.